{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:26:27Z","timestamp":1780395987616,"version":"3.54.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Previous research has shown that both temozolomide (TMZ) and PD-1\/L1 inhibitors (PD-1\/L1) alone exhibit certain potential in the treatment of non-small cell lung cancer (NSCLC) with brain metastases (BM), in this study, we will explore combining the two in order to seek new effective treatment options for NSCLC with BM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Material and methods<\/jats:title>\n                <jats:p>During 2021.1 to 2023.12, we collected the date of these pretreated-NSCLC with BM who accept the treatment of TMZ and PD-1\/L1, the objective response ratio (ORR), progression-free survival (PFS) and overall survival (OS) were set as the primary endpoint, meanwhile, the toxicity of such regimen was also recorded.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>About 42 patients are enrolled, our primary analysis demonstrated that the ORR of such regimen toward NSCLC with BM was 26.19%, with Approximate intracranial and extracranial lesion ORR was 6% and 20% respectively, the DCR was about 64.29%, the mean PFS and OS was about 4\u00a0m and 8.5\u00a0m. Further analysis indicated that the efficiency correlated with the diagnosis-Specific Graded Prognostic Assessment (ds-GPA) score. Moreover, the toxicity can also be tolerated, indicating the application potential of such regimen against NSCLC with BM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our results exhibited that with tolerated toxicity, the combination of TMZ and PD-1\/L1 shows promising efficiency against NSCLC with BM, this would be of great significance for the treatment of NSCLC with brain metastasis. However, due to the limitation of sample and retrospective property, the real value of such regimen needed to be further confirmed in the future.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-024-05808-0","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T14:02:55Z","timestamp":1716472975000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The efficiency and safety of temozolomide and PD-1\/L1 inhibitors in pretreated NSCLC with brain metastasis: a retrospective cohort"],"prefix":"10.1007","volume":"150","author":[{"given":"Xiaobing","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuebing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"issue":"9","key":"5808_CR1","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1002\/cncr.23859","volume":"113","author":"R Addeo","year":"2008","unstructured":"Addeo R, De Rosa C, Faiola V et al (2008) Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases. Cancer 113(9):2524\u20132531. https:\/\/doi.org\/10.1002\/cncr.23859","journal-title":"Cancer"},{"issue":"5","key":"5808_CR2","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/s1470-2045(20)30207-2","volume":"21","author":"F Barlesi","year":"2020","unstructured":"Barlesi F, Tomasini P (2020) Non-small-cell lung cancer brain metastases and PD-(L)1 immune checkpoint inhibitors. Lancet Oncol 21(5):607\u2013608. https:\/\/doi.org\/10.1016\/s1470-2045(20)30207-2","journal-title":"Lancet Oncol"},{"issue":"6","key":"5808_CR3","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1200\/jco.22.01503","volume":"41","author":"JR Brahmer","year":"2023","unstructured":"Brahmer JR, Lee JS, Ciuleanu TE et al (2023) Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in CheckMate 227. J Clin Oncol 41(6):1200\u20131212. https:\/\/doi.org\/10.1200\/jco.22.01503","journal-title":"J Clin Oncol"},{"issue":"9","key":"5808_CR4","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1093\/annonc\/mdl146","volume":"17","author":"AB Cortot","year":"2006","unstructured":"Cortot AB, Gerini\u00e8re L, Robinet G et al (2006) Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study. Ann Oncol 17(9):1412\u20131417. https:\/\/doi.org\/10.1093\/annonc\/mdl146","journal-title":"Ann Oncol"},{"issue":"5","key":"5808_CR5","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000018455","volume":"99","author":"H Duan","year":"2020","unstructured":"Duan H, Zheng SY, Zhou T, Cui HJ, Hu KW (2020) Temozolomide plus whole brain radiotherapy for the treatment of non-small-cell lung cancer patients with brain metastases: a protocol of an updated systematic review and meta-analysis. Medicine 99(5):e18455. https:\/\/doi.org\/10.1097\/md.0000000000018455","journal-title":"Medicine"},{"key":"5808_CR6","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.lungcan.2016.05.031","volume":"98","author":"E Dudnik","year":"2016","unstructured":"Dudnik E, Yust-Katz S, Nechushtan H et al (2016) Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases. Lung Cancer 98:114\u2013117. https:\/\/doi.org\/10.1016\/j.lungcan.2016.05.031","journal-title":"Lung Cancer"},{"issue":"16","key":"5808_CR7","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1158\/1078-0432.Ccr-20-0798","volume":"26","author":"I Eguren-Santamaria","year":"2020","unstructured":"Eguren-Santamaria I, Sanmamed MF, Goldberg SB et al (2020) PD-1\/PD-L1 blockers in NSCLC brain metastases: challenging paradigms and clinical practice. Clin Cancer Res 26(16):4186\u20134197. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-0798","journal-title":"Clin Cancer Res"},{"key":"5808_CR8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.lungcan.2018.12.017","volume":"128","author":"SM Gadgeel","year":"2019","unstructured":"Gadgeel SM, Lukas RV, Goldschmidt J et al (2019) Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: exploratory analyses of the phase III OAK study. Lung Cancer 128:105\u2013112. https:\/\/doi.org\/10.1016\/j.lungcan.2018.12.017","journal-title":"Lung Cancer"},{"issue":"11","key":"5808_CR9","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1200\/jco.22.01989","volume":"41","author":"MC Garassino","year":"2023","unstructured":"Garassino MC, Gadgeel S, Speranza G et al (2023) Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study. J Clin Oncol 41(11):1992\u20131998. https:\/\/doi.org\/10.1200\/jco.22.01989","journal-title":"J Clin Oncol"},{"issue":"2","key":"5808_CR10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.lungcan.2005.05.026","volume":"50","author":"CG Giorgio","year":"2005","unstructured":"Giorgio CG, Giuffrida D, Pappalardo A et al (2005) Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: phase II study. Lung Cancer 50(2):247\u2013254. https:\/\/doi.org\/10.1016\/j.lungcan.2005.05.026","journal-title":"Lung Cancer"},{"issue":"7","key":"5808_CR11","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/s1470-2045(16)30053-5","volume":"17","author":"SB Goldberg","year":"2016","unstructured":"Goldberg SB, Gettinger SN, Mahajan A et al (2016) Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol 17(7):976\u2013983. https:\/\/doi.org\/10.1016\/s1470-2045(16)30053-5","journal-title":"Lancet Oncol"},{"issue":"8","key":"5808_CR12","doi-asserted-by":"publisher","first-page":"4711","DOI":"10.21873\/anticanres.11877","volume":"37","author":"Q He","year":"2017","unstructured":"He Q, Bi X, Ren C et al (2017) Phase II study of the efficacy and safety of high-dose pemetrexed in combination with cisplatin versus temozolomide for the treatment of non-small cell lung cancer with brain metastases. Anticancer Res 37(8):4711\u20134716. https:\/\/doi.org\/10.21873\/anticanres.11877","journal-title":"Anticancer Res"},{"issue":"2","key":"5808_CR13","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/annonc\/mdy551","volume":"30","author":"KM Heinhuis","year":"2019","unstructured":"Heinhuis KM, Ros W, Kok M, Steeghs N, Beijnen JH, Schellens JHM (2019) Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Ann Oncol 30(2):219\u2013235. https:\/\/doi.org\/10.1093\/annonc\/mdy551","journal-title":"Ann Oncol"},{"issue":"7","key":"5808_CR14","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.jtho.2019.02.009","volume":"14","author":"LEL Hendriks","year":"2019","unstructured":"Hendriks LEL, Henon C, Auclin E et al (2019) Outcome of patients with non-small cell lung cancer and brain metastases treated with checkpoint inhibitors. J Thorac Oncol 14(7):1244\u20131254. https:\/\/doi.org\/10.1016\/j.jtho.2019.02.009","journal-title":"J Thorac Oncol"},{"issue":"23","key":"5808_CR15","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.2217\/fon-2020-0156","volume":"16","author":"C Henon","year":"2020","unstructured":"Henon C, Remon J, Hendriks LE (2020) Combination treatments with immunotherapy in brain metastases patients. Future Oncol 16(23):1691\u20131705. https:\/\/doi.org\/10.2217\/fon-2020-0156","journal-title":"Future Oncol"},{"issue":"1","key":"5808_CR16","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ijrobp.2020.04.018","volume":"108","author":"AFC Hulsbergen","year":"2020","unstructured":"Hulsbergen AFC, Mammi M, Nagtegaal SHJ et al (2020) Programmed death receptor ligand one expression may independently predict survival in patients with non-small cell lung carcinoma brain metastases receiving immunotherapy. Int J Radiat Oncol Biol Phys 108(1):258\u2013267. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.04.018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"5808_CR17","doi-asserted-by":"publisher","first-page":"7072","DOI":"10.1007\/s12035-018-0905-3","volume":"55","author":"V Jindal","year":"2018","unstructured":"Jindal V, Gupta S (2018) Expected paradigm shift in brain metastases therapy-immune checkpoint inhibitors. Mol Neurobiol 55(8):7072\u20137078. https:\/\/doi.org\/10.1007\/s12035-018-0905-3","journal-title":"Mol Neurobiol"},{"issue":"2","key":"5808_CR18","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s11060-014-1435-0","volume":"118","author":"G Minniti","year":"2014","unstructured":"Minniti G, Scaringi C, Lanzetta G et al (2014) Whole brain reirradiation and concurrent temozolomide in patients with brain metastases. J Neurooncol 118(2):329\u2013334. https:\/\/doi.org\/10.1007\/s11060-014-1435-0","journal-title":"J Neurooncol"},{"issue":"11","key":"5808_CR19","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/jco.22.01990","volume":"41","author":"S Novello","year":"2023","unstructured":"Novello S, Kowalski DM, Luft A et al (2023) Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study. J Clin Oncol 41(11):1999\u20132006. https:\/\/doi.org\/10.1200\/jco.22.01990","journal-title":"J Clin Oncol"},{"issue":"2","key":"5808_CR20","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/s1470-2045(20)30641-0","volume":"22","author":"L Paz-Ares","year":"2021","unstructured":"Paz-Ares L, Ciuleanu TE, Cobo M et al (2021) First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol 22(2):198\u2013211. https:\/\/doi.org\/10.1016\/s1470-2045(20)30641-0","journal-title":"Lancet Oncol"},{"issue":"11","key":"5808_CR21","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/j.jtho.2021.06.020","volume":"16","author":"SF Powell","year":"2021","unstructured":"Powell SF, Rodr\u00edguez-Abreu D, Langer CJ et al (2021) Outcomes with pembrolizumab plus platinum-based chemotherapy for patients with NSCLC and stable brain metastases: pooled analysis of KEYNOTE-021, -189, and -407. J Thorac Oncol 16(11):1883\u20131892. https:\/\/doi.org\/10.1016\/j.jtho.2021.06.020","journal-title":"J Thorac Oncol"},{"issue":"7","key":"5808_CR22","first-page":"732","volume":"1","author":"HI Robins","year":"2006","unstructured":"Robins HI, Traynor AM, Mehta M (2006) Temozolomide as prophylaxis for brain metastasis in non-small cell lung cancer. J Thorac Oncol 1(7):732\u2013733","journal-title":"J Thorac Oncol"},{"issue":"7","key":"5808_CR23","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/s1470-2045(16)30091-2","volume":"17","author":"R Rosell","year":"2016","unstructured":"Rosell R, Karachaliou N (2016) Trends in immunotherapy for brain metastases. Lancet Oncol 17(7):859\u2013860. https:\/\/doi.org\/10.1016\/s1470-2045(16)30091-2","journal-title":"Lancet Oncol"},{"issue":"3","key":"5808_CR24","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.ijrobp.2009.08.025","volume":"77","author":"PW Sperduto","year":"2010","unstructured":"Sperduto PW, Chao ST, Sneed PK et al (2010) Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 77(3):655\u2013661. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.08.025","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"5808_CR25","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.ijrobp.2012.11.042","volume":"85","author":"PW Sperduto","year":"2013","unstructured":"Sperduto PW, Wang M, Robins HI et al (2013) A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. Int J Radiat Oncol Biol Phys 85(5):1312\u20131318. https:\/\/doi.org\/10.1016\/j.ijrobp.2012.11.042","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"5808_CR26","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41571-019-0320-3","volume":"17","author":"JH Suh","year":"2020","unstructured":"Suh JH, Kotecha R, Chao ST, Ahluwalia MS, Sahgal A, Chang EL (2020) Current approaches to the management of brain metastases. Nat Rev Clin Oncol 17(5):279\u2013299. https:\/\/doi.org\/10.1038\/s41571-019-0320-3","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"5808_CR27","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.jtho.2021.04.014","volume":"16","author":"V Teixeira Loiola de Alencar","year":"2021","unstructured":"Teixeira Loiola de Alencar V, Guedes Camandaroba MP, Pirolli R, Fogassa CAZ, Cordeiro de Lima VC (2021) Immunotherapy as single treatment for patients with NSCLC with brain metastases: a systematic review and meta-analysis-the META-L-BRAIN study. J Thorac Oncol 16(8):1379\u20131391. https:\/\/doi.org\/10.1016\/j.jtho.2021.04.014","journal-title":"J Thorac Oncol"},{"issue":"4","key":"5808_CR28","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1200\/jco.23.01524","volume":"42","author":"D Uprety","year":"2024","unstructured":"Uprety D, Remon J, Peters S (2024) First-line dual immunotherapy, a treatment option in first-line metastatic non-small-cell lung cancer: are we ready to use it? J Clin Oncol 42(4):378\u2013382. https:\/\/doi.org\/10.1200\/jco.23.01524","journal-title":"J Clin Oncol"},{"issue":"51","key":"5808_CR29","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000023592","volume":"99","author":"Y Yang","year":"2020","unstructured":"Yang Y, Pu Y, Dai N, Wang D, Xu M (2020) Complete response of radioresistant brain metastases from non-small cell lung cancer with temozolomide: a case report and literature review. Medicine 99(51):e23592. https:\/\/doi.org\/10.1097\/md.0000000000023592","journal-title":"Medicine"},{"issue":"11","key":"5808_CR30","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2217\/imt-2017-0052","volume":"9","author":"H Zheng","year":"2017","unstructured":"Zheng H, Zeltsman M, Zauderer MG, Eguchi T, Vaghjiani RG, Adusumilli PS (2017) Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy. Immunotherapy 9(11):913\u2013927. https:\/\/doi.org\/10.2217\/imt-2017-0052","journal-title":"Immunotherapy"},{"issue":"17","key":"5808_CR31","doi-asserted-by":"publisher","first-page":"942","DOI":"10.21037\/atm-22-4208","volume":"10","author":"X Zhu","year":"2022","unstructured":"Zhu X, Dong S, Tang J et al (2022) Lung cancer with brain metastases remaining in continuous complete remission due to pembrolizumab and temozolomide: a case report. Ann Transl Med 10(17):942. https:\/\/doi.org\/10.21037\/atm-22-4208","journal-title":"Ann Transl Med"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05808-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-024-05808-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05808-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T03:25:25Z","timestamp":1717989925000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-024-05808-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["5808"],"URL":"https:\/\/doi.org\/10.1007\/s00432-024-05808-0","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,23]]},"assertion":[{"value":"28 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). This retrospective trial was approved by the Ethics Committee of Hubei Cancer Hospital Affiliated to Tongji Medical College (Wuhan, China) (No. HBCHEC2021121), and patients or their families signed an informed consent form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"As the study was retrospective and data collection anonymized, the informed consent of patients was not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"271"}}